SINGAPORE - An injectable drug used to treat obesity is now available via prescription from any licensed physician in ...

A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Ongoing research is needed to fully understand their risks, especially for long-term and higher-dose users. However, many ...

Dr Rowan French insists lasting weight loss can only be achieved through a balanced approach to psychology, exercise and ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

As the popularity of medications for weight loss, such as Ozempic and Wegovy, surges across North America, new research ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

The state law gives Gov. Lamont "an enormous amount of negotiating leverage with the industry," Sen. Lesser said.

The drug coverage provision does not mention any specific drug by name, but it could include the GLP-1 agonists, such as ...

A recent survey highlighted a widespread lack of understanding about the much-publicised GLP-1 weight-loss medications ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...